Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(®)) in immunodeficiency diseases: real-life data from a monocentric experience
Francesca Angelotti, Riccardo Capecchi, Daiana Giannini, O. Mazzarella, Valeria Rocchi, Paola Migliorini
Topics & Concepts
TolerabilityMedicineDiscontinuationAdverse effectInternal medicineImmunologySubcutaneous injectionAntibodyImmunodeficiency and Autoimmune DisordersPlatelet Disorders and TreatmentsBlood disorders and treatments